

Docket No. 1217-0156P

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application.

The specification has also been amended to be in better form.

The claims have been amended to correct improper multiple dependencies and to place them in better condition for examination.

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Leonard R. Svensson, #30,330

LRS/lmt
1217-0156P

P.O. Box 747
Falls Church, VA 22040-0747
(714) 708-8555

Attachment: VERSION WITH MARKINGS TO SHOW CHANGES MADE

Docket No. 1217-0156P

VERSION WITH MARKINGS TO SHOW CHANGES MADEIN THE SPECIFICATION:

The paragraph beginning on page 6, line 36, has been deleted.

The paragraph beginning on page 6, line 32, has been amended as follows:

The present invention also relates to a modified peptide essentially constituted by a peptide linked, by a hydrazide link, to at least one compound A [bearing , before its link to said peptide, a function selected from the group formed by carboxylic acid functions and alcohol functions] selected from the group formed by lipids, sugars, alcohols and fluorescence markers.

The paragraph beginning on page 7, line 26, has been amended as follows:

The present invention further relates to the use of N,N'-tri(Boc)hydrazinoacetic acid or N,N'-di(Boc)hydrazinoacetic acid for functionalizing a peptide intended to be linked according to the above coupling process, in the event of the hydrazine group borne by the peptide being an α -hydrazinoacetic group, with this taking place prior to step b), with an α -hydrazinoacetic acid, either at the N-terminal end of said peptide or at the end of the

Docket No. 1217-0156P

side chain of a lysine or of an ornithin possibly present at some point in the peptide sequence.

IN THE CLAIMS:

The claims have been amended as follows:

5°) (AMENDED) Process according to claim 2 [any one of claims 2 to 4], characterized by the fact that said hydrazine derivative group borne by the peptide is an α -hydrazinoacetic group.

8°) (AMENDED) Process according to claim 1 [any one of the preceding claims], characterized in that said compound A is selected from the group constituted by lipids, sugars, alcohols and fluorescence markers.

11°) (AMENDED) Modified peptide, characterized in that it is essentially constituted by a peptide linked, by a hydrazide link, to at least one compound A [bearing , before its link to said peptide, a function selected from the group constituted by the carboxylic acid functions and the alcohol functions] selected from the group constituted by lipids, sugars, alcohols and fluorescence markers.

12°) (AMENDED) Modified peptide according to claim 11, characterized in that it is an oligopeptide essentially constituted by a peptide linked, by a hydrazide link, to at least

Docket No. 1217-0156P

one lipid [compound] selected from the group constituted by [lipids, sugars, alcohols and fluorescence markers] saturated fatty acids, unsaturated fatty acids and sterols.

13°) (AMENDED) Modified peptide according to claim 12, characterized in that it is an oligopeptide essentially constituted by a peptide linked, by a hydrazide link, to at least one lipid selected from the group constituted by [saturated fatty acids, unsaturated fatty acids and sterols] palmitic acid, stearic acid, cis-9,10-epoxystearic acid, oleic acid, linoleic acid and cholesterol.

14°) (AMENDED) Synthetic vaccine, characterized in that it includes at least one modified peptide according to any one of claims 11 to 13 [Modified peptide according to claim 13, characterized in that it is an oligopeptide essentially constituted by a peptide linked, by a hydrazide link, to at least one lipid selected from the group constituted by palmitic acid, stearic acid, cis-9,10-epoxystearic acid, oleic acid, linoleic acid and cholesterol].

15°) (AMENDED) [Synthetic vaccine] Diagnosis reagent, characterized in that it includes at least one modified peptide according to any one of claims 11 to 13 [14].

16°) (AMENDED) [Diagnosis reagent, characterized in that it

includes at least one modified peptide according to any one of claims 11 to 14] Use of the residue of the process according to claim 1 for the preparation of a medicament including an active principal of a vectorized peptidic nature, useful for cell targeting.

17°) (AMENDED) Use of [the process according to any one of claims 1 to 10 for the preparation of a medicament including an active principal of a vectorized peptidic nature, useful for cell targeting] N,N'-tri(Boc)hydrazinoacetic acid or of N,N'-di(Boc)hydrazinoacetic acid for functionalizing a peptide designed to be linked according to the process according to claim 5, with this taking place prior to step b), with an α -hydrazinoacetic group, either at the N-terminal end of said peptide or at the end of the side chain of a lysine or of an ornithin possibly present at some point in the peptide sequence.